Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.